AU
UK
CA
NZ
IND
US
Shares of XBiotech Inc. (NASDAQ:XBIT) traded above their 50-day moving average during the January 30 session, touching an intraday high of USD 2.56. The stock’s 50-day average stood at USD 2.49, while the 200-day moving average was higher at USD 2.67. Despite the intraday …
STAAR Surgical (NASDAQ:STAA) saw its price objective reduced by Jefferies Financial Group, which lowered its target to USD 21.50 from USD 28.00. Despite the cut, the firm reiterated a buy-equivalent rating, suggesting continued confidence in the company’s longer-term fundamentals even as near-term valuation assumptions …
Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage biotechnology company, announced the completion of patient enrollment in its Phase 2/3 DRAGON II clinical trial for tinlarebant, a treatment under investigation for Stargardt disease type 1 (STGD1). The study enrolled 60 adolescent subjects, including 15 participants from …
UnitedHealth Group Incorporated (NYSE:UNH) saw its shares decline steeply in pre-market trading on January 27 after reporting weakerearningsand issuingrevenueguidance for fiscal year 2026 that fell below the prior year’s level.
Shares of Rapt Therapeutics (NASDAQ:RAPT) climbed 64% on Tuesday to close at USD 57.57, following the announcement that the immunology-focused biotechnology company had agreed to be acquired by British pharmaceutical group GSK (NYSE: GSK). Under the terms of the agreement, GSK will acquire Rapt …
Shares of ImmunityBio Inc. (NASDAQ:IBRX) closed Thursday’s session at USD 3.95, marking a30.79% gain for the day. The move followed the company’s release of preliminary full-year 2025 results, which outlined a substantial increase in revenue from its bladder cancer therapy, Anktiva. Over the past …
Shares ofImmunityBio, Inc. (NASDAQ:IBRX)were recently the subject of updated analyst commentary afterD. Boral Capitalreiterated its stock rating in a research note issued to investors. The brokerage maintained a price objective ofUSD 24.00, reflecting its outlook on the biotechnology company following recent developments.
In a recent sequence of research notes, several brokerages and ratings services updated their assessments ofKORU Medical Systems, Inc. (NASDAQ:KRMD), reflecting a range of opinions on the medical device maker’s prospects. On Monday, investment analysis firmWall Street Zenrevised its view on KRMD, moving the …
Coya Therapeutics (NASDAQ:COYA) remains under analyst coverage following a research note from Chardan Capital, which reaffirmed its “buy” rating on the stock, according to a report cited by Benzinga. The brokerage maintained a price target of USD 14.00, referencing its assessment of the company’s …
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by Morgan Stanley, which shifted its rating on the stock from “overweight” to “equal weight” in a research note issued earlier this week. The brokerage maintained a price objective of USD 19.00 while adjusting its overall stance on the …
Please wait processing your request...